SUMMARY IgM antibody capture radioimmunoassays were developed to detect coxsackie virus B1-B5 specific IgM. Specific IgM was detected in sera from all patients with coxsackie B virus infections proved by isolation; however, sera from 13/32 patients with rising neutralising antibody titres were negative in the assay. Frequent heterotypic responses were seen among the positive sera. Thirty seven patients with other enterovirus infections were also studied, and sera from 15 of these patients reacted in the assay, showing that heterotypic coxsackie B IgM responses occur not only in coxsackie B virus infections but also in other enterovirus infections. Specimens from control patients Twenty consecutive sera sent for routine syphilis serology from adult patients (mean age 50 years (range 25-82)) admitted to a psychiatric hospital and 20 sera collected from well children (mean age 7*5 years (range 3-12)) admitted to hospital for routine orthopaedic operations were used as control sera.
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Coxsackie B viruses have been implicated in a number of serious infections of the myocardium and pericardium. Coxsackie B virus is rarely isolated in these conditions, however, and serological diagnosis by the neutralisation test has proved unsatisfactory.
Specific IgM antibody has been found in patients with coxsackie B virus infections using neutralising antibody and 2-mercaptoethanol treatment ' and immunoelectrophoresis.2 These methods, however, are not suitable for routine diagnostic use. Recently, El-Hagrassy et al3 showed that an IgM antibody capture enzyme assay could detect coxsackie B specific IgM in patients with recent infections and in some patients with heart disease. These authors used a mixed antigen containing coxsackie B virus types 1-5, however, and therefore heterotypic reactions within the group could not be investigated. Furthermore, sera from patients with other enterovirus infections were not studied. The test was performed in Abbott 20 well reaction trays using 6 5 mm etched polystyrene balls (Northumbria Biologicals) for the solid phase. The beads were washed three times between each stage of the test with phosphate buffered saline containing 0-05% TWEEN 20. The diluent for all stages of the test was phosphate buffered saline with 0-05% TWEEN 20 and 10% fetal calf serum and the reaction volume was 0-2 ml.
The beads were coated overnight at +4°C with goat antihuman ,u-chain specific affinity purified Pugh antibody (TAGO) diluted 1/2000 in 0-05 M carbonate-bicarbonate buffer pH 9-6 using 0-2 ml per bead. The beads were then washed and distributed into the reaction wells, and test sera diluted 1/100 was added and incubated at 37°C for 2 h. At this stage the antigens, diluted 1/2, were added and incubated for 18 h at room temperature. The sera were tested against coxsackie B serotypes 1-5 and control antigen. After this the rabbit coxsackie B antisera diluted 1/3000 in diluent were added and incubated for 2 h at 37°C. Finally, the labelled goat antirabbit IgG diluted to 25 000 counts/min/well was added and incubated at 37°C for 2 h. After final washing the beads were transferred to tubes and counted for 300s on a Nuclear Enterprises 1600 gamma counter. Positive and negative control sera were tested for each antigen. The results were expressed as the ratio between the counts from the test serum and those of the negative contol serum (P/N ratio). antihuman A-chain coating serum in the MACRIA test using positive and negative control sera. A positive control P/N ratio of about 20 and a label binding of about 8% were obtained at the optimum coating dilution. The positive control serum which was broadly reactive gave similar ratios for all serotypes.
Results
The positive control serum was tested at dilutions from 1/100 to 1/51 200 (Fig. 2 ). The highest P/N ratios were found at 1/100-1/200, but specific activity was still detected at 1/51 200. The antigens were tested at dilutions from neat to 1/512 using positive control serum at 1/100. The P/N values fell off rapidly at dilutions greater than 1/4 (Fig. 3 ). All these experiments were performed with the five antigens with very similar results, but only the Bi results are shown for clarity. The rabbit antisera used for antigen detection were type specific in this assay. A chessboard titration was set up testing each rabbit antiserum against each coxsackie B antigen, using anti-,-chain coated beads previously incubated with positive control serum to bind the antigen. The results for each antiserum were expressed as a percentage of the binding to homologous antigen. The heterotypic binding of each antiserum was in all cases 10% or less of its binding to homologous antigen (Table 1) . obtained from the control groups are shown in Table  2 . As enterovirus infections are extremely common some positive results were expected among these sera, especially from children.
The mean P/N values +2 standard deviations did not exceed 3 for any serotype in the adult sera. This value was exceeded only for B5 in the sera from healthy children. One of these sera gave a P/N ratio of 7 for B5, which distorted the result for this serotype. Accordingly, a P/N ratio of 3 was selected as the cut off point for the purposes of this study. None of the control or test sera in this study reacted with control antigen.
COXSACKIE B INFECTIONS
The initial work with this test was done with sera showing fourfold rises in neutralising antibody titre to one or more coxsackie B serotypes. The IgM responses in these sera were extremely varied and the correlation between rising neutralising antibody titres and the MACRIA responses was not good (Table 3 ). Only 9/21 sera with monotypic rising neutralising antibody titres were positive by MAC-RIA, but of the MACRIA positive sera 8/9 contained IgM which reacted with the same serotype as the neutralising antibody rise. There were 11 sera with rising neutralising antibody titres to two or more serotypes, and all but one of these was MAC-RIA positive. Sera from 11 patients from whom coxsackie B viruses were isolated were studied. The difference between these and the rising titre sera was striking ( A striking finding in this study was that 40% of the sera with rising coxsackie B neutralising antibody titres were negative in the MACRIA. There may be several explanations for this finding. The sensitivity of the MACRIA may be insufficient, although this seems unlikely. The sera could be from patients with reinfections, which might result in little IgM response. This also seems unlikely in view of the fact that all the sera from patients from whom coxsackie B viruses were isolated were IgM positive, and coxsackie B IgM is boosted by other enterovirus infections. A third possibility is that the sera were from patients with other enterovirus infections which had boosted the coxsackie B neutralising antibody titre non-specifically. Since there was poor correlation between neutralising antibody and the MACRIA result, suggesting that different antigens are concerned, it would not be surprising if enterovirus infections sometimes boosted the neutralising antibody titre without affecting the MAC-RIA result and vice versa.
The coxsackie B MACRIA as described is of limited value as a routine diagnostic test because the heterotypic responses are unpredictable in individual patients. It may, however, prove useful for studying specific conditions such as diabetes or heart disease, where large numbers can be studied with appropriate controls.
The test might be improved in two ways. The antigen used in the MACRIA was unpurified, and it is possible that the specificity could be improved with either purified whole virus or viral polypeptides. Although this should be investigated in detail, this would entail the use of many different purified reagents and would be unsuitable for routine diagnostic use. An alternative approach would be to use multiple or disrupted antigens in order to detect group specific IgM. A test which detects enterovirus specific IgM antibody, although less useful for epidemiological purposes than a specific test, would certainly be of clinical value.
